Idorsia Ltd (SWX:IDIA)
4.315
+0.500 (13.11%)
Sep 30, 2025, 5:31 PM CET
Idorsia Revenue
Idorsia had revenue of 72.24M CHF in the quarter ending June 30, 2025, with 341.89% growth. This brings the company's revenue in the last twelve months to 217.22M, up 69.92% year-over-year. In the year 2024, Idorsia had annual revenue of 112.51M, down -26.17%.
Revenue (ttm)
217.22M
Revenue Growth
+69.92%
P/S Ratio
3.68
Revenue / Employee
334.19K
Employees
650
Market Cap
798.54M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 112.51M | -39.88M | -26.17% |
Dec 31, 2023 | 152.39M | 55.28M | 56.93% |
Dec 31, 2022 | 97.10M | 61.75M | 174.70% |
Dec 31, 2021 | 35.35M | -36.41M | -50.74% |
Dec 31, 2020 | 71.76M | 47.94M | 201.26% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Roche Holding AG | 63.49B |
Novartis AG | 43.89B |
Lonza Group AG | 7.09B |
Galderma Group AG | 3.73B |
Alcon | 7.97B |
Sandoz Group AG | 8.42B |
Straumann Holding AG | 2.58B |
Sonova Holding AG | 3.87B |
Idorsia News
- 8 days ago - Global expansion of Idorsia's QUVIVIQ continues as Simcere launches in China - GlobeNewsWire
- 11 days ago - Idorsia's JERAYGO (aprocitentan) approved in Switzerland for the treatment of resistant hypertension - Benzinga
- 11 days ago - Idorsia's JERAYGO (aprocitentan) approved in Switzerland for the treatment of resistant hypertension - GlobeNewsWire
- 15 days ago - Idorsia Ltd (IDRSF) Special Call - Slideshow - Seeking Alpha
- 20 days ago - Idorsia shares new analyses of daridorexant for patients with insomnia at World Sleep 2025 - GlobeNewsWire
- 22 days ago - Idorsia Ltd (IDRSF) TRYVIO Investor Q&A Webcast And Conference Call (Transcript) - Seeking Alpha
- 22 days ago - Idorsia highlights very low real-world abuse potential of DORA class for insomnia treatment at WSC 2025 - GlobeNewsWire
- 25 days ago - Idorsia to collaborate with two leading academic medical centers to launch IMPACT-HTN - a US initiative to transform care for patients with difficult-to-control hypertension - PRNewsWire